Oxford completes US$91 million sale of newly constructed, 140,000 SF Boston GMP facility to pioneering biotech firm Moderna

Written By Hayley Norman

Originally acquired by Oxford as a development and investment opportunity in 2021, the transaction highlights continued institutional demand for best-in-class biomanufacturing space

Hayley Norman
Previous

Oxford breaks ground on 165,000 sq ft expansion of Ionis Pharmaceuticals Carlsbad campus
Next

Blog Post Title Three